1 – 7 of 7
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 1998
-
Mark
Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model
(
- Contribution to journal › Article
- 1996
-
Mark
Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor
(
- Contribution to journal › Article
-
Mark
Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?
(
- Contribution to journal › Article
- 1994
-
Mark
Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin(TM)). An experimental investigation in healthy volunteers
(
- Contribution to journal › Article
-
Mark
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis : A comparison with low molecular weight heparin
(
- Contribution to journal › Article
- 1993
-
Mark
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
(
- Contribution to journal › Article